

Preclinical pipeline update


- 6. 4Q update
- 7. Closing remarks



Product candidate	Preclinical	Phase 1	Phase 2	Collaborator
	Melanoma Combination w/Keytruda			
ONCOS-200 series	Next Gen viruses			leidos
				Papyrus
Novel mutRAS				
concepts				OBLIQUE THERAPEUTICS



TARGOVAX'S THREE-PILLAR R&D PIPELINE STRATEGY



Novel ONCOS-102 combinations

- Maximize clinical impact of ONCOS-102 through novel clinical combinations with complementary mechanism of action
- Strong scientific rationale from existing clinical immune data



Next Generation ONCOS viruses

- Build new functionality into clinically proven ONCOS backbone
- Boosted immunological activity and anti-tumor ammunition
- Proprietary development and external collaborations




Mutant RAS vaccination

- Novel combinations and adjuvant technology for TG vaccines
- Next generation mutant RAS vaccination strategies
- Incorporate immune activation capability of ONCOS technology



NEXT GENERATION ONCOS: ONCOS-211 PRIORITIZED FOR FURTHER DEVELOPMENT

Adenosine – a key suppressor of immune cells



Transgene activity

Transgene 1 – ICOS-L

- ICOS-ligand binds to ICOS on the Tcell surface, providing a strong stimulatory signal
- Enhanced cytotoxicity

Transgene 2 – ADA

- ADA degrades adenosine released by the tumor
- Reversal of immune-suppressive tumor micro-environment


Virus activity

- 1. Innate immune activation
- 2. Cancer cell oncolysis
- 3. Adaptive anti-tumor immune response




ICOS-L EXPRESSION CAN BE TIED TO DEEP CLINICAL RESPONSE TO ONCOS-102

Immune cell infiltrate at Baseline, mIHC



Co-stimulatory receptor expression, gene expression




69 Unpublished company data



BUILDING TYROSINE KINASE INHIBITOR FUNCTIONALITY INTO ONCOS

Collaboration partner

Target – Tyrosine kinase inhibition



- OPCML is a **potent tumor suppressor**, inactivated in ca. 50% of all cancers
- OPCML shuts down the oncogenic signaling function of at least 8 RTKs
- OPCML suppresses epithelial-to-mesenchymal (EMT) transition


Using ONCOS to restore OPCML activity represents a novel and highly targeted mechanism of kinase inhibition in multiple cancer indications





NOVEL MUTANT RAS VACCINATION CONCEPTS INCORPORATING IMMUNOLOGICAL POWER OF ONCOS

PeptiCRAd



peptides

Merging ONCOS and TG technology


VALO

ONCOS used as carrier for mutRAS peptides

Combining the power of mutRAS vaccination and oncolysis

71

THE R&D PIPELINE STRATEGY IS DESIGNED TO ADDRESS KEY COMPONENTS OF THE CANCER IMMUNITY CYCLE



- IFNg induction
- Upregulation of T-cell killing machinery
 - Tumor growth inhibition/EMT suppression (Papyrus)

Α